Cardiff Oncology Presents Novel Preclinical Data At AACR Annual Meeting 2024; Supports First-Line RAS-Mutated mCRC Clinical Study

– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth –

– Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutated first-line mCRC –

Therapeutic areas outside of RAS-mutated mCRC

– In RAS-wild type mCRC, onvansertib demonstrates antitumor activity in preclinical models as a single agent and in combination with cetuximab, highlighting that onvansertib activity in mCRC can be independent of RAS mutational status –

– In SCLC and ovarian cancer, robust preclinical data underscore onvansertib's activity in combination treatments across multiple tumors –